| abstract |
The present invention relates to ethyl (2S)-2-(naphthalene-1-sulfonylamino)- 3- (4-(2-(1,4,5,6-tetrahydropyrimidin-2- ylcarbamoyl)ethyl)benzoylamino)propionate hemifumarate of formula (I), and t o a process for its preparation comprising react- ing 4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoic acid or a derivative thereof and ethyl (2S)-3-amino-2-(naphtha- lene-1-sulfonylamino)propionate. The compound of formula (I) is a valuable pharmaceutical which can be used, for example, in the treatment or prophylaxis of diseases which can be influenced by inhibiting t he vitronectin receptor, in particular of bone diseases such as osteoporosis. The invention furthermore relates to chemical intermediates useful for the preparation of the compound of formula (I). |